📊 SKYE Key Takeaways
Is Skye Bioscience, Inc. (SKYE) a Good Investment?
Skye Bioscience is in severe financial distress with no meaningful revenue, $43.1M annual operating cash burn, and only $5.9M in cash reserves—creating an estimated runway of 1-2 months before liquidity crisis. Deeply negative profitability metrics (ROE -279%, ROA -197%) combined with deteriorating EPS (-93% YoY) indicate the company is not on a viable path to commercialization or profitability.
Why Buy Skye Bioscience, Inc. Stock? SKYE Key Strengths
- Minimal debt burden ($45.6K long-term debt) reduces refinancing risk
- Positive stockholders' equity of $20M provides some balance sheet cushion
- Low financial leverage preserves bankruptcy distance
SKYE Stock Risks: Skye Bioscience, Inc. Investment Risks
- Critical cash runway: $5.9M cash against $43.1M annual burn equals 1-2 months to depletion
- Zero revenue generation suggests failed commercialization or pre-revenue stage in capital-intensive pharma sector
- Severely deteriorating fundamentals with EPS down 93% YoY and persistent operating losses of $58M+
Key Metrics to Watch
- Cash balance and monthly burn rate trajectory
- Announcements of financing, partnerships, or revenue-generating catalysts
- Operating expense reduction initiatives and path to profitability
Skye Bioscience, Inc. (SKYE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.30x current ratio provides a solid financial cushion.
SKYE Profit Margin, ROE & Profitability Analysis
SKYE vs Healthcare Sector: How Skye Bioscience, Inc. Compares
How Skye Bioscience, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Skye Bioscience, Inc. Stock Overvalued? SKYE Valuation Analysis 2026
Based on fundamental analysis, Skye Bioscience, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Skye Bioscience, Inc. Balance Sheet: SKYE Debt, Cash & Liquidity
SKYE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Skye Bioscience, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.73 indicates the company is currently unprofitable.
SKYE Revenue Growth, EPS Growth & YoY Performance
Skye Bioscience, Inc. Dividends, Buybacks & Capital Allocation
SKYE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Skye Bioscience, Inc. (CIK: 0001516551)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SKYE
What is the AI rating for SKYE?
Skye Bioscience, Inc. (SKYE) has an AI rating of STRONG SELL with 97% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SKYE's key strengths?
Claude: Minimal debt burden ($45.6K long-term debt) reduces refinancing risk. Positive stockholders' equity of $20M provides some balance sheet cushion.
What are the risks of investing in SKYE?
Claude: Critical cash runway: $5.9M cash against $43.1M annual burn equals 1-2 months to depletion. Zero revenue generation suggests failed commercialization or pre-revenue stage in capital-intensive pharma sector.
What is SKYE's revenue and growth?
Skye Bioscience, Inc. reported revenue of N/A.
Does SKYE pay dividends?
Skye Bioscience, Inc. does not currently pay dividends.
Where can I find SKYE SEC filings?
Official SEC filings for Skye Bioscience, Inc. (CIK: 0001516551) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SKYE's EPS?
Skye Bioscience, Inc. has a diluted EPS of $-1.41.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SKYE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Skye Bioscience, Inc. has a STRONG SELL rating with 97% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SKYE stock overvalued or undervalued?
Valuation metrics for SKYE: ROE of -279.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SKYE stock in 2026?
Our dual AI analysis gives Skye Bioscience, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SKYE's free cash flow?
Skye Bioscience, Inc.'s operating cash flow is $-43.1M, with capital expenditures of $6.3K.
How does SKYE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -279.3% (avg: 15%), current ratio 3.30 (avg: 2).